title: Continuous administration of nicorandil decreases QT dispersion during the chronic phase of acute myocardial infarction.
abstract: We previously reported that continuous intravenous (IV) administration of nicorandil (NIC) inhibits QT dispersion (QTd). However, no prior study has evaluated the efficacy of NIC when administered orally to acute myocardial infarction (AMI) patients following continuous IV administration. Thirty patients with anteroseptal infarction in whom revascularization was performed successfully within 6 hours of AMI onset were included in the study and assigned to one of 3 groups: group A (continuous IV administration of NIC), group B (continuous IV and oral administration of NIC), and group C (no treatment with NIC). After 24 hours, QTd in groups A and B was significantly decreased compared to QTd in group C (P < 0.01) (group A, 58.1; group B, 58.2; and group C, 81.3). The QTd obtained 3 months later was significantly shorter in group B subjects who were orally administered NIC, and QTd before percutaneous coronary intervention (PCI) was restored in group A, in which no NIC had been administered orally [group A, 66.7; group B, 54.1; and group C, 73.9; P < 0.05 (group A versus group B) and P < 0.01 (group B versus group C)]. The effects were evaluated by comparing different routes of administration. Continuous IV and subsequent oral administration of NIC inhibited prolongation of QTd, suggesting that these effects may prevent the occurrence of cardiac events during both the acute and chronic phases of AMI.
authors.affiliation: Department of Cardiology, Rakuwakai Otowa Hospital, Kyoto, Japan.
authors.forename: Tadasu
authors.initials: T
authors.lastname: Akagi
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Sarazawa
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Inai
authors.forename: Motoaki
authors.initials: M
authors.lastname: Kitagawa
authors.forename: Nobuki
authors.initials: N
authors.lastname: Takahashi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hamanaka
authors.forename: Taketoshi
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Masato
authors.initials: M
authors.lastname: Takebe
authors.forename: Norio
authors.initials: N
authors.lastname: Hama
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hiraoka
authors.forename: Kinzo
authors.initials: K
authors.lastname: Ueda
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Nakazawa
authors.forename: Naoki
authors.initials: N
authors.lastname: Matsumoto
mesh_terms: D000284:Administration, Oral; D000368:Aged; D004452:Echocardiography; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D009204:Myocardial Revascularization; D020108:Nicorandil / Q000008:administration & dosage* / Q000494:pharmacology; D011379:Prognosis; D013318:Stroke Volume; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000494:pharmacology; D016277:Ventricular Function, Left
chemical_list: D014665:Vasodilator Agents; D020108:Nicorandil